{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:35Z","timestamp":1740138515181,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01755-3","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T08:03:50Z","timestamp":1660637030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804)"],"prefix":"10.1007","volume":"39","author":[{"given":"Atsushi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3427-4558","authenticated-orcid":false,"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","volume":"85","author":"JA Barta","year":"2019","unstructured":"Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:8.","journal-title":"Ann Glob Health"},{"key":"1755_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Paz-Ares L, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"W Wang","year":"2021","unstructured":"Wang W, Roy S, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356.","journal-title":"Nat Med"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu T-E, P\u00e9rol M, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665\u201373.","journal-title":"Lancet"},{"key":"1755_CR6","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","volume":"16","author":"Y Yoneshima","year":"2021","unstructured":"Yoneshima Y, Nakamura A, Okamoto I, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16:1523\u201332.","journal-title":"J Thorac Oncol"},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Berille J, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095\u2013103.","journal-title":"J Clin Oncol"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Bunn Jr PA, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589\u201397.","journal-title":"J Clin Oncol"},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10147-019-01396-z","volume":"24","author":"S Sugawara","year":"2019","unstructured":"Sugawara S, Nakagawa K, Tamura T, et al. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. Int J Clin Oncol. 2019;24:485\u201393.","journal-title":"Int J Clin Oncol"},{"key":"1755_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Fukushimashirasaka M, et al. Anticancer Drugs. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"key":"1755_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/annonc\/mdv190","volume":"26","author":"K Kubota","year":"2015","unstructured":"Kubota K, Sugawara S, Kudoh S, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 2015;26:1401\u20138.","journal-title":"Ann Oncol"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/annonc\/mds629","volume":"24","author":"H Yoshioka","year":"2013","unstructured":"Yoshioka H, Okamoto I, Nakagawa K, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013;24:1326\u201331.","journal-title":"Ann Oncol"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/annonc\/mdl377","volume":"18","author":"Y Ohe","year":"2007","unstructured":"Ohe Y, Ohashi Y, Fukuoka M, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317\u201323.","journal-title":"Ann Oncol"},{"key":"1755_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10120-011-0009-5","volume":"14","author":"H Narahara","year":"2011","unstructured":"Narahara H, Iishi H, Sakata Y, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301\/TOP-002). Gastric Cancer. 2011;14:72\u201380.","journal-title":"Gastric Cancer"},{"key":"1755_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000328739","volume":"80","author":"Y Komatsu","year":"2011","unstructured":"Komatsu Y, Yuki S, Asaka M, et al. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology. 2011;80:70\u20135.","journal-title":"Oncology"},{"key":"1755_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10147-008-0796-9","volume":"14","author":"O Ishimoto","year":"2009","unstructured":"Ishimoto O, Ishida T, Sugawara S, et al. Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. Int J Clin Oncol. 2009;14:43\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1755_CR17","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.2007.11.8646","volume":"25","author":"H Suehisa","year":"2007","unstructured":"Suehisa H, Toyooka S, Date H, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol. 2007;25:3952\u20137.","journal-title":"J Clin Oncol"},{"key":"1755_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/1535-7163.MCT-07-0567","volume":"7","author":"T Okabe","year":"2008","unstructured":"Okabe T, Okamoto I, Nakagawa K, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008;7:599\u2013606.","journal-title":"Mol Cancer Ther"},{"key":"1755_CR19","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/cas.12275","volume":"104","author":"T Kohno","year":"2013","unstructured":"Kohno T, Tsuta K, Goto K, et al. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci. 2013;104:1396\u2013400.","journal-title":"Cancer Sci"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1158\/1535-7163.MCT-09-1009","volume":"9","author":"K Takezawa","year":"2010","unstructured":"Takezawa K, Okamoto I, Nakagawa K, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9:1647\u201356.","journal-title":"Mol Cancer Ther"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-0511","volume":"14","author":"I Okamoto","year":"2008","unstructured":"Okamoto I, Sugawara S, Nakagawa K, et al. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505. Clin Cancer Res. 2008;14:5250\u20134.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1755_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000331681","volume":"81","author":"K Akie","year":"2011","unstructured":"Akie K, Oizumi S, Nishimura M, et al. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601. Oncology. 2011;81(2):84\u201390.","journal-title":"Oncology"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00280-012-1957-0","volume":"70","author":"H Goya","year":"2012","unstructured":"Goya H, Kuraishi H, Koizumi T, et al. Phase I\/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70:691\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jjco\/hyu226","volume":"45","author":"S Ikemura","year":"2015","unstructured":"Ikemura S, Naoki K, Soejima K, et al. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 2015;45:356\u201361.","journal-title":"Jpn J Clin Oncol"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Yi-Long Wu, Fukuoka M, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.bjc.6600725","volume":"88","author":"S Negoro","year":"2003","unstructured":"Negoro S, Masuda N, Fukuoka M, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003;88:335\u201341.","journal-title":"Br J Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01755-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T05:24:28Z","timestamp":1663219468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01755-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01755-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Atsushi Nakamura received honoraria from MSD and Eli Lilly and Company. Akira Inoue received honoraria from Taiho Pharmaceutical. Shunichi Sugawara received honoraria from Taiho Pharmaceutical. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our manuscript is sufficiently anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"163"}}